During the 1997-1998 measles epidemic in Poland a high attack rate occurred in infants up to 1 year of age (24.6/100,000 in comparison with 5.5/100,000 in total population). Routine vaccination against measles for infants aged 13-15 months was introduced in Poland in 1975, and a second dose added in 1991. The recommended age for measles vaccination was based on information gathered in years when most mothers had a natural measles. Nowadays, many mothers have received measles vaccine. Early loss of passively acquired measles antibody may occur in infants of women who received measles vaccine, because measles vaccine induces lower antibody titres than does natural infection. Therefore, measles-specific antibody titres were determined among vaccinated and unvaccinated women as well as among infants, whose mothers were born after 1976 and likely were vaccinated (Group 1), and those, whose mothers were born before 1969 and likely have had a natural measles (Group 2). All women that were born in prevaccination era had significantly higher geometric mean titre (GMT) of measles antibody than those who were vaccinated (P<0.001). Also infants from Group 2 at every age had higher GMT of measles antibody than those of Group 1. The antibody decay was significantly faster among infants whose mothers acquired immunity by measles vaccination. Because nowadays the majority of women in childbearing age are vaccinated against measles, earlier vaccination in the infants should be considered.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/s0264-410x(03)00113-0 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
A Roadmap Towards the Identification and Validation of Conserved T Cell Epitope Regions in Viral Pathogen Families with Pandemic Potential.
Curr Pharm Biotechnol
January 2025
Center for Vaccine Innovation, La Jolla Institute for Immunology (LJI), La Jolla, CA 92037, USA.
The SARS-CoV-2 pandemic has highlighted the need for society, as a whole, to be prepared against potential pandemics caused by a variety of different viral families of concern. Here, we describe a roadmap towards the identification and validation of conserved T cell epitope regions from Viral Families of Pandemic Potential (VFPP). For each viral family, we select a prototype virus, the sequence of which could be utilized in epitope identification screens.
View Article and Find Full Text PDFParental Factors Associated With Measles-Mumps-Rubella Vaccination in US Children Younger Than 5 Years.
Am J Public Health
January 2025
Eric Geng Zhou is with the Center for Child Health Services Research, Icahn School of Medicine at Mount Sinai, New York, NY. Jonathan Cantor is with RAND, Santa Monica, CA. Autumn Gertz, John S. Brownstein, and Benjamin Rader are with Innovation and Digital Health Accelerator, Boston Children's Hospital, Boston, MA. Brian Elbel is with the Department of Population Health, Grossman School of Medicine, New York University, New York.
To determine the association between parental characteristics and MMR (measles-mumps- rubella) vaccination status of children in the United States. We conducted a cross-sectional study from July 2023 to April 2024 using a digital health survey via OutbreaksNearMe, weighted to target national population characteristics. We analyzed the responses of 19 892 parents of children younger than 5 years to examine the association between self-reported parental characteristics (i.
View Article and Find Full Text PDFVaccination coverage, delay and loss to follow-up of the triple viral vaccine, in live births between 2017 and 2018 in Brazilian cities.
Epidemiol Serv Saude
January 2025
Universidade de Brasília, Brasília, DF, Brazil.
Objective: To estimate measles-mumps-rubella vaccination coverage, delay and loss to follow-up in children up to 24 months old living in Brazilian cities.
Methods: Surveys and questionnaires with a retrospective cohort of live births in 2017-2018, analyzing vaccination coverage and sociodemographic data of children and families, based on vaccination card records and interviews.
Results: Valid coverage of first dose was 90.
Unveiling immunity gaps and determining a suitable age for a third dose of the measles-containing vaccine: a strategic approach to accelerating measles elimination.
Lancet Reg Health Southeast Asia
January 2025
Department of Tropical Hygiene, Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand.
Background: In highly measles immunized countries, immunity gaps in adolescents and young adults are a key issue posing an obstacle to measles elimination. This study aims to identify the gaps by estimating the age-stratified probability of seropositivity, and to ascertain a suitable age for the administration of a third dose of a measles-containing vaccine (MCV3) to effectively fill these gaps.
Methods: We retrospectively obtained measles serological results from hospital setting among among individuals aged 13-39 years and developed a serocatalytic dynamic probability model, stratifying seropositivity due to vaccination or natural infection.
Examining homology between MPXV and immunogenic VACV-derived peptides.
Vaccine
January 2025
Mayo Clinic Vaccine Research Group, Mayo Clinic, Rochester, MN 55905, USA. Electronic address:
The mpox virus (MPXV) came to global attention with the 2022 global outbreak. Current vaccination and post-exposure prophylaxis against MPXV consists of live vaccinia whole virus-based vaccines including ACAM2000®, JYNNEOS™, and LC16m8 originally developed against smallpox. Here, we analyzed 152 vaccinia-derived peptides we identified by mass spectrometry for homology with MPXV-1 and MPXV-2 sequences to evaluate their potential relevance to MPXV-specific immunity.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!